Iron sorbitex

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H596206

CAS#: 62765-90-6

Description: Iron Sorbitex is indicated for the treatment of Iron Sorbitex deficiency anemia in patients with chronic kidney disease. Iron Sorbitex is an Iron Sorbitex replacement product indicated for the treatment of Iron Sorbitex deficiency anemia in patients with chronic kidney disease.

Chemical Structure

img
Iron sorbitex
CAS# 62765-90-6
Instruction

Theoretical Analysis

Hodoodo Cat#: H596206
Name: Iron sorbitex
CAS#: 62765-90-6
Chemical Formula: C12H19FeO13
Exact Mass: 427.02
Molecular Weight: 427.110
Elemental Analysis: C, 33.75; H, 4.48; Fe, 13.07; O, 48.70

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Iron sorbitex; HSDB 1967; Astra 1572; Yectofer; Jectofer; Iron Sorbitol;

IUPAC/Chemical Name: Iron-sorbitol

InChi Key: WNDUPUMWHYAJOR-SADXPQEKSA-K

InChi Code: InChI=1S/C6H8O7.C6H14O6.Fe/c7-3(8)1-6(13,5(11)12)2-4(9)10;7-1-3(9)5(11)6(12)4(10)2-8;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);3-12H,1-2H2;/q;;+3/p-3/t;3-,4+,5-,6-;/m.1./s1

SMILES Code: O=C([O-])CC(C([O-])=O)(O)CC([O-])=O.OC[C@](O)([H])[C@](O)([H])[C@@](O)([H])[C@](O)([H])CO.[Fe+3]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 427.11 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Urbach A, Brueckner J, Witte OW. Cortical spreading depolarization stimulates gliogenesis in the rat entorhinal cortex. J Cereb Blood Flow Metab. 2015 Mar 31;35(4):576-82. doi: 10.1038/jcbfm.2014.232. PubMed PMID: 25515215; PubMed Central PMCID: PMC4420877.

2: Afzal M, Qureshi SM, Lutafullah M, Iqbal M, Sultan M, Khan SA. Comparative study of efficacy, tolerability and compliance of oral iron preparations (iron edetae, iron polymatose complex) and intramuscular iron sorbitol in iron deficiency anaemia in children. J Pak Med Assoc. 2009 Nov;59(11):764-8. PubMed PMID: 20361676.

3: Galleano M, Lemberg A, Puntarulo S. Does hepatomegaly alter iron-dependent oxidative effects in human plasma? Hum Exp Toxicol. 2003 Jul;22(7):401-5. PubMed PMID: 12929730.

4: Poljak-Blazi M, Kralj M, Hadzija MP, Zarković N, Zarković K, Waeg G. Involvement of lipid peroxidation, oncogene expression and induction of apoptosis in the antitumorous activity of ferric-sorbitol-citrate. Cancer Biother Radiopharm. 2000 Jun;15(3):285-93. PubMed PMID: 10941536.

5: Poljak-Blazi M, Zarkovic N, Schaur RJ. Impaired proliferation and DNA synthesis of a human tumor cell line (HeLa) caused by short treatment with the anti-anemic drug jectofer (ferric-sorbitol-citrate) and the lipid peroxidation product 4-hydroxynonenal. Cancer Biother Radiopharm. 1998 Oct;13(5):395-401. PubMed PMID: 10851431.

6: Gupta R, Gupta S, Joshi K, Ganguly NK. Role of iron and iron chelation therapy in oxygen free radical mediated tissue injury in an ascending mouse model of chronic pyelonephritis. Comp Immunol Microbiol Infect Dis. 1997 Sep;20(4):299-307. PubMed PMID: 9481514.

7: Sunder-Plassmann G, Hörl WH. Safety aspects of parenteral iron in patients with end-stage renal disease. Drug Saf. 1997 Oct;17(4):241-50. Review. PubMed PMID: 9352960.

8: Bechensteen AG, Halvorsen S, Skottner A. Recombinant human insulin-like growth factor 1 (rh-IGF-1) stimulates erythropoiesis in adult, but not in newborn mice. Acta Physiol Scand. 1994 May;151(1):117-23. PubMed PMID: 8048331.

9: Voest EE, Neijt JP, Keunen JE, Dekker AW, van Asbeck BS, Nortier JW, Ros FE, Marx JJ. Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. Cancer Chemother Pharmacol. 1993;31(5):357-62. PubMed PMID: 8431969.

10: Dabbagh AJ, Blake DR, Morris CJ. Effect of iron complexes on adjuvant arthritis in rats. Ann Rheum Dis. 1992 Apr;51(4):516-21. PubMed PMID: 1586252; PubMed Central PMCID: PMC1004704.

11: Raica M. Calciphylaxis induced by iron-citrate sorbitol. Exp Pathol. 1990;38(3):196-200. PubMed PMID: 2358062.

12: Wei SL, Li ZJ, He YK, Huang H, Chen ZS. [Studies on the physical properties of iron sorbitol]. Yao Xue Xue Bao. 1984 Oct;19(10):785-9. Chinese. PubMed PMID: 6544031.

13: Bernát SI, Soós G. [A new method for the determination of iron concentration in urine and its use in intramuscular iron load for the reliable and early detection of iron deficiency conditions]. Folia Haematol Int Mag Klin Morphol Blutforsch. 1983;110(3):437-46. German. PubMed PMID: 6194078.

14: Callender ST. Treatment of iron deficiency. Clin Haematol. 1982 Jun;11(2):327-38. Review. PubMed PMID: 7042154.

15: Guze LB, Guze PA, Kalmanson GM, Glassock RJ. Effect of iron on acute pyelonephritis and later chronic changes. Kidney Int. 1982 Jun;21(6):808-12. PubMed PMID: 6752529.

16: Winter R, Seidel A. The influence of an iron-sorbitol-citrate complex on the deposition of monomeric 239Pu in four rodent species. Health Phys. 1981 Jan;40(1):100-4. PubMed PMID: 7216769.

17: Lindvall S, Rydén L, Smedgärd P, Swedberg B. Alpha-tocopherol and cardiac toxicity of iron. Scand J Haematol. 1980 Oct;25(4):331-8. PubMed PMID: 7209402.

18: Smith FW, Dendy PP, Pocklington T, Dawson AA, Foster MA, Mallard JR. A preliminary investigation of 67Ga citrate distribution in hyperferraemic patients. Eur J Nucl Med. 1980 Aug;5(4):327-32. PubMed PMID: 7398669.

19: Scott DE, Saltin AS, Pritchard JA. Iron sorbitex for treating iron-deficiency anemia. Obstet Gynecol. 1967 Nov;30(5):679-82. PubMed PMID: 6053103.

20: Evaluation of an iron preparation for intramuscular use. Iron sorbitex (jectofer). JAMA. 1966 Jul 11;197(2):135-6. PubMed PMID: 5952496.